QGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Qiagen NV is not a strong buy for a beginner, long-term investor at this moment. The technical indicators show a bearish trend, options data suggests low bullish sentiment, and hedge funds are selling. While the company's financials show growth in revenue and net income, the gross margin decline and lack of recent positive news or catalysts make it less appealing. Analysts' ratings and price targets are mixed, with some downgrades and reduced takeover potential. The stock may not align with the user's preference for a strong long-term investment opportunity.
The technical indicators for QGEN show a bearish trend. The MACD is negative and expanding downward, RSI indicates the stock is oversold at 16.441, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 38.276), with resistance at R1: 42.043.
The company's financials for Q4 2025 show revenue growth of 3.69% YoY, net income growth of 22.09% YoY, and EPS growth of 28.95% YoY, which are positive indicators of operational performance.
Gross margin dropped by -6.85% YoY, hedge funds are selling heavily (286.76% increase in selling), and analysts have downgraded the stock citing reduced takeover potential and increased risks from competitors like Roche entering key markets.
In Q4 2025, Qiagen reported revenue of $540.42M (up 3.69% YoY), net income of $107.83M (up 22.09% YoY), and EPS of 0.49 (up 28.95% YoY). However, gross margin declined to 59.83% (down -6.85% YoY).
Analyst ratings are mixed. Recent downgrades include Barclays reducing the price target from $58 to $44 and downgrading to Equal Weight. Morgan Stanley raised the price target slightly to EUR 44 but maintained an Equal Weight rating. Deutsche Bank upgraded the stock to Buy citing valuation and balance sheet strength but noted limited takeover prospects. The consensus outlook is cautious with no strong bullish sentiment.
